News & Updates

Elevated nonhigh-density lipoprotein cholesterol (non–HDL-C) levels in childhood that persist into adulthood poses an increased risk of cardiovascular disease (CVD), according to a study. But the good news is that the resolution of dyslipidaemic non–HDL-C levels adulthood may help prevent CVD events.

For patients with multiple sclerosis (MS) who are receiving treatment with natalizumab, getting shots with inactivated vaccines is safe and immunogenic, with the positive results persisting regardless of the duration of natalizumab therapy, as shown in a study.

Use of panobinostat in combination with vincristine and irinotecan chemotherapy provides effective tumour response in models developed from patients with high-risk, relapsed, and treatment-refractory hepatoblastoma (HB), according to a study.

For patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD) cirrhosis, treatment with glucagon-like peptide-1 receptor agonists helps reduce the risk of hepatic decompensation, portal hypertension, hepatocellular carcinoma, and liver transplantation, according to a study.

A second pre-eclampsia does not lead to worse outcomes relative to the first occurrence, suggests a study. On the contrary, some clinical features and effects appear to be better in the second event.

Treatment with mycophenolate mofetil (MMF) in combination with prednisolone results in better biochemical remission rates at 24 weeks than the use of azathioprine plus prednisolone in patients with treatment-naïve autoimmune hepatitis (AIH), reports a study.